ClinicalTrials.gg
CompletedNCT00152373Updated Dec 3, 2013

Double-blind, Placebo-controlled Study of Levetiracetam in Adults With POS

A Phase 3 interventional study of Levetiracetam in Epilepsy, Partial, sponsored by UCB Pharma. Completed. Open to participants aged 16 Years to 70 Years. Per ClinicalTrials.gov, last updated 2013-12-03.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3 and Interventional

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
192
Allocation
Randomized
Ages
16 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 18 studies testing levetiracetam in Epilepsies, Partial — none open to participants now, none under way, none of them phase 3. Levetiracetam · Epilepsies, Partial.

Enrollment
9th of 18
192 · median 173
Started
2004
with 4 others
Phase 3
10 of 18
none open now
Registered
3rd of 18
by date
Lead sponsor
10 of 18
UCB Pharma

Among the 18 studies testing levetiracetam in Epilepsies, Partial, this one is the 9th largest by enrollment, is one of 5 that started in 2004, is one of 10 in phase 3, and was the 3rd registered.

Epilepsies, Partial

243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.

Browse Epilepsies, Partial studies →

Open to participants now

None of the 18 studies testing levetiracetam in Epilepsies, Partial is open now. The open studies under Epilepsies, Partial, anywhere →

About levetiracetam

Levetiracetam: first FDA approval 1999 (KEPPRA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.

This study: 16 Years to 70 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing levetiracetam in Epilepsies, Partial as a file.
02

Study summary

clinical efficacy and safety of Levetiracetam as add-on therapy in adult Chinese subjects with partial seizures.

03

Conditions studied

  • Epilepsy, Partial

Keywords

  • Epilepsy, Partial Onset Seizures; Keppra; Levetiracetam
04

Who can participate

Ages eligible
16 Years to 70 Years
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. subject suffering from partial onset seizures, whether or not secondarily generalized,
  2. presence of the following during the eight weeks of the historical baseline period: at least eight partial seizures (type IA, IB or IC) with or without secondary generalization.
  3. subject on a stable dose of at least one and no more than two other concomitant antiepileptic drugs (AEDs).
  4. subject who has been exposed to at least one classical AEDs,
  5. CT scan or MRI performed within the last 2 years and free of neoplasia, progressive cerebral disease or any other progressively neurodegenerative disease.

Exclusion criteria

Exclusion Criteria:

  1. history of status epilepticus within three months prior to the Selection visit,
  2. subjects whose seizures cannot reliably be counted on a regular basis due to their fast and repetitive occurrence (clusters or flurries),
  3. use of any medication (other than the concomitant AED) that influences the central nervous system (CNS) unless on a stable regimen for at least 1 month prior to the Selection visit. Antidepressants (except amitriptyline, mianserin and fluoxetine), anxiolytics and hypnotics are allowed. Intermittent benzodiazepines are allowed as long as the frequency is not greater than one single administration per week for at least 3 months prior to the Selection visit. Neuroleptics and Traditional Chinese AEDs are not allowed.,
  4. history or presence of pseudoseizures,
05

Study design

Phase
Phase 3
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
192 participants

Interventions

06

What researchers measure

Primary outcomes

  1. The partial onset (type I) seizure frequency reduction per week over the 16-week treatment period (titration and maintenance)

Secondary outcomes

  1. Seizure freedom ;

  2. The partial onset (type I) seizure reduction response rate ;

  3. Safety and tolerability

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2004, a primary completion of May 2005 and a completion of May 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2005
First posted
Sep 9, 2005
Start
Jul 2004
Primary completionActual
May 2005
CompletionActual
May 2005
Last update
Dec 3, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00152373
Lead sponsor
UCB Pharma
First posted
Sep 9, 2005
Start date
Jul 2004
Primary completion
May 2005
Completion
May 2005
Last update
Dec 3, 2013

Study contacts

UCB Clinical Trial Call Center
study director · UCB Pharma
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levetiracetam

Start the discussion